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1 Introduction
Despite advances in perinatal care, serious mor-
bidity among small preterm infants still necessi-
ates pronged, expensive neonatal care. While an
increased number of infants with respiratory dis-
tress syndrome (RDS) survive, a considerable pro-
portion of them may develop chronic debilitating
disease, known as bronchopulmonary dysplasia
(BPD) [18, 21]. Thus, a prevention of the long
term morbidity among the small preterm infants
with lung immaturity is a great challenge. Since
lack of surfactant is the main cause of RDS,
surfactant supplementation could be an effective
method to prevent the morbidity associated with
immaturity. Natural surfactant, applied to imma-
ture animal lung causes a striking acute improve-
ment in respiratory function [1, 11, 12], whereas
the synthetic surfactant preparations have had
modest acute effects, if any. Following the report
of FUJIWARA [4], natural surfactant has been
mainly used in clinical trials. Non-randomized
studies have demonstrated that surfactant substi-
tution acutely improves the oxygenation and de-
creases the respiratory support [3, 4, 9, 24]. Only
well-designed, randomized studies can evaluate
objectively the ri$ks and benefits of surfactant
supplementation.
2 Natural surfactant
Composition: "Natural" surfactant consists of un-
ique proteins [14] and lipids [6]. Surfactant is con-
sidered to be "natural" when its principal compo-
nents are derived from the lung. Extensive investi-
gation is required to establish a "new" surfactant
to be used in therapy [20]. Table I highlights the
Table I. Natural surfactants used in clinical trials.
Natural surfactant Dose Placebo Retreatment Reference
Lipid extract of bovine lung
+ synthetic phospholipids
TA-surfactant: lipid extract of a fraction
of bovine lung + synthetic lipids
Lipid extract of calf lung lavage
Lipid extract of calf lung lavage
Chromatographie fraction of the lipid
extract of porcine or bovine lung
Phospholipid-rich complex from human
amniotic fluid by differential and
density gradient centrifugation
150mg/kg
55 or 108 mg/kg
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features of the natural surfactants that have been
used in clinical trials. Only the human surfactant
from amniotic fluid contains the disulfide-linked
oligomer, composed of polypeptide units of 35
kDalton glycoprotein. This protein enhances the
biological activity of synthetic phospholipids,
saturated phosphatidylcholine and phosphatidyl-
glycerol [22] and it is a structural component of
the tubular myelin [26]. All natural surfactants
contain low molecular weight proteolipid(s). The
small molecular weight surfactant proteolipids
(5 — 18 kDalton) enhance greatly the surface ad-
soprtion of phospholipids, thereby allowing satu-
rated phosphatidylcholine to concentrate on inter-
phases and eliminate the surface forces. Liposo-
mes containing synthetic phospholipids and the
surfactant proteolipid may approach the activity
of the natural surfactant in stabilizing the alveoli
of surfactant deficient lungs. Besides the bio-
chemical composition, the biophysical micellar
form is another issue that influences the biological
activity. Many surfactants, including that from
human amniotic fluid, consist mainly of multi-
lamellar structures.
Availability: Heterologous surfactant from animal
lungs may become available for treatment of
RDS. Human surfactant may be harvested from
amniotic fluid and distrivuted from "surfactant
banks" for treatment of RDS (figure 1). Human
surfactant should be the model for the "natural"
surfactant produced by available biomedical tech-
niques in unlimited quantities.
Administration and dosage: According to current
practice, surfactant is introduced through an en-
dotracheal tube as a bolus of 3 to 5 ml using a
saline vehicle to small preterm infants (table I). In
preterm lambs at birth a bolus of 60 mg/kg re-
sulted in maximal acute improvement in respirat-
ory failure [11]. A similar dose, given in RDS to
small preterm infants permanently improved the
respiratory function only in 50% of the cases,
whereas in the others the response was unsatisfac-
tory or it vanished resulting in a relapse of respir-
atory failure [7]. Exogenous surfactant decreased
concomitant with the relapse [8]. Altogether 22
out of 31 of immature small preterm infants re-
ceiving 60 mg human surfactant within ten min-
utes of birth required retreatment because of
(mostly mild) respiratory failure [17]. Most infants
responded favorably to retreatment (figure 2),
whereas in 8% of the infants the alleviation of the
respiratory failure was transient despite retreat-
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Figure 1. Amount of saturated phosphatidylcholine pre-
sent in amniotic fluid that was nearly quantitatively
recovered by suctioning the amnionic cavity during term
cesarean section. In polyhydramnion due to lack of fetal
swallowing, there is often large quantities of surfactant,
apparently because the major pathway of surfactant
elimination via gastrointestinal tract was decreased. The
amount of saturated phosphatidylcholine in amniotic
fluid correlates closely with the amount of surfactant
that can be isolated. A mean of 14 mg surfactant was
recovered from amniotic fluid suctioned during term
cesarean section. Considering the incidence of the elec-
tive term cesarean section with intact mertfbranes
(5-15%) and of RDS (0.3-1%), there should be
enough amniotic fluid surfactant for treatment of all
cases of RDS.
peared from the airways with a half life of 30
(range 20 — 36) hours there was no relapse of
respiratory failure since the amount of endoge-
nous surfactant in the airways increased [8]. The
occasional therapeutic failure can be due to sur-
factant inhibitors or exceptionally rapid disap-
pearance of exogenous surfactant from the air-
ways. Furthermore, exogenous surfactant does
not distribute evenly in peripheral airways in
severe lung injury [13].
According to animal studies prophylactic surfac-
tant at birth is more efficacious than surfactant
given in respiratory failure [12]. The superiority
of "prophylactic" to "rescue" surfactant has not
yet been demonstrated in a concurrent clinical
trial.
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Figure 2. Acute effects of surfactant on the arterial Ρθ2 ^
divided by the alveolar Ρθ2 (a/A Ρθ2), and on the mean "o
airway pressure (cm FhO). The data is obtained from c
patients treated in University Central Hospital, Helsinki. <j
The amount of surfactant in the rescue trial was 60 mg/ |(
kg or a minimum of 60 mg, whereas in separate study ^
surfactant was given already at birth using a dose of 60 ^
mg. Retreatment was indicated when fractional inspira- §
tory oxygen requirements exceeded 0.5, or when in- g
creases of peak inspiratory pressures were necessary to *G




3 Surfactant substitution in management of res- '·§
piratory failure 3
Randomized clinical trials: Table II lists the present 3
randomized clinical trials thus far. Many others α
are underway. The infants, who were given bovine t3
surfactant before the first breath had a lower <§
incidence of RDS than the controls who were ^
given air [2]. It is unclear, whether bovine surfac- °
tant actually prevented RDS, since the degree of ;§
biochemical lung maturity was not studied. &
'SSide effects: The dramatic improvement in gas ·|
exchange could be envisioned as having undesir- jo
able circulatory consequences. FUJIWARA ob- g
served cardiorespiratory failure due to left to right &
shunting through the patent ductus arteriosus B
(PDA) following bovine surfactant [3, 4]. Others 3
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PDA shunting [2, 7, 17]. Indomethacin prior to
surfactant did not improve the remission of the
respiratory failure [5]. Indeed, the ductus ar-
teriosus may constrict shortly after exogenous sur-
factant administration. The left to right shunt
through PDA needs to be closely surveyed and
promptly treated, since the limited reserve of the
left ventricle could result in severe cardiac failure,
pulmonary edema, and proteinacecous inhibitors
"leaking" into the airspaces.
Some patients have demonstrated a transient de-
crease in the blood pressure following surfactant
instillation. This phenomenon may be due to acute
vasodilatation, possibly as a result of an oxygen-
induced increase in prostacyclin and a decrease in
platelet-derived tromboxane (unpublished re-
sults). The risk can be eliminated by infusing
blood volume expanders before surfactant.
Present evidence suggests that exogenous surfac-
tant does not inhibit the endogenous secretion.
Instead, it could provide substates for a rate limit-
ing step in endogenous surfactant synthesis, and
stimulate the secretion of endogenous surfactant
[8].
Surfactant could conceivably be antigenic when
administered intratracheally, thus raising concerns
about the potential for sensitization or imrnuno-
logic injury on infants so treated. STRAYER et al.
demonstrated a transient increase in surfactant-
anti-surfactant immunocomplex formation in
RDS regardless whether they had received exogen-
ous human surfactant. This observation suggests
that in RDS surfactant gains access to the systemic
circulation; however, there was no evidence of
immunocomplex-related disease detectable by
clinical or by serologic means [25]. No antibodies
against exogenous animal surfactant were de-
tected in six survivors with RDS [19]. This issue is
still unsettled because of lack of adequate studies.
Antibody formation against surfactant proteins
must be rigorously excluded prior to suggesting
the safety of heterologous surfactant.
A drug may contain microbes or toxins. All natu-
ral surfactants used in clinical trials are reportedly
free from bacteria, fungi or even viruses. Today,
our human surfactant undergoes heat treatment to
eliminate HI virus. No toxic reactions, including
pyrogen reactions, have thus far been reported
although continuous surveillance is required.
Does surfactant improve the outcome of small pre-
term infants? Randomized trials in small preterm
infants have demonstrated that surfactant substi-
tution decreases the occurrence of acute complica-
tions, pulmonary interstitial emphysema and
Pneumothorax (table II). There has been no de-
tectable (i.e. more than 50%) decrease in the
incidence of intraventricular hemorrhage or PDA,
whereas the incidence of death and BPD decreased
following human surfactant (table II). Thus far,
there are neither published cost benefit analyses
nor follow up data.
Possible indications of exogenous surfactant: RDS
is a spectrum of diseases involving infants with
various degrees of "immaturity" and other abnor-
malities [6]. In adult respiratory distress syndrome
serious surfactant defects are virtually always pre-
sent, too [10]. Exogenous surfactant has a favor-
able response in respiratory failure in animals,
regardless of the etiology [16]. Therefore, the indi-
cations of surfactant therapy can be wider than
expected merely on the basis of the trials published
at present. It is hoped that the more general avail-
ability of surfactant for therapeutic purposes does
not result in injudicious practise but instead stimu-
lates research on a wide variety of issues that
eventually maximize the benefits and minimize the
side effects of this potent therapy.
Summary
Natural surfactants consist of unique proteins and lipids.
Their effectiveness in improving subnormal lung func-
tion in surfactant deficiency should be established prior
to any clinical trials. Rigorous tests are required to
document batch to batch variability in surface activity
and to exclude toxic contaminants. Up to this date
randomized clinical trials in small preterm infants have
demonstrated a striking improvement in lung function,
and a decrease in incidence of acute complications
(pneumothorax, interstitial emphysema). Administra-
tion of human surfactant at birth or in severe RDS
decreased deaths and incidence of bronchopulmonary
dysplasia. Although homologous surfactant may not be
more advantageous than the heterologous one in terms
J. Perinat. Med. 15 (1987)
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of its acute beneficial effects on lung function, the safety
and efficacy of animal surfactant in improving the out-
come remains to be established. Human surfactant may
serve as a model for unlimited natural surfactant pro-
duced by gene technology. The pharmacodynamic as-
pects of surfactant substitution, the indications of ex-
ogenous surfactant, and the management of the patients
undergoing surfactant substitution remain to be studied.
Exogenous surfactant offers a potential to treat or pre-
vent severe respiratory failure in infants, children and
adults.
Keywords: Amniotic fluid, hyaline membrane disease, surfactant.
Zusammenfassung
Gabe von natürlichem Surfactant beim Atemnotsyndrom
(RDS)
Der natürliche Surfactant besteht aus ganz bestimmten
Proteinen und Lipiden. Deren Effizienz zur Verbesse-
rung einer normalen Lungenfunktion bei Surfactant-
mangel sollte vor der klinsichen Erprobung bewiesen
werden. Es sind strenge Kontrollen notwendig, um
Schwankungen hinsichtlich der Oberflächenaktivität bei
verschiedenen Produktionsserien zu dokumentieren und
toxische Kontaminationen ausschließen zu können. Bei
randomisierten klinischen Studien mit kleinen Frühge-
borenen zeigte sich eine deutliche Verbesserung der Lun-
genfunktion und eine geringere Inzidenz akuter Kompli-
kationen (Pneumothorax, interstitielles Emphysem).
Nach Gabe von Surfactant vom Menschen bei Geburt
oder bei schwerem RDS war die Inzidenz von Todesfal-
len und bronchopulmonalen Dysplasien geringer. Ob-
wohl der homologe Surfactant gegenüber dem heterolo-
gen im Hinblick auf die akute Verbesserung der Lungen-
funktion möglicherweise keine Vorteile bietet, muß die
Sicherheit und Effizienz des Surfactants vom Tier zur
Verbesserung des neonatalen Zustandes erst noch bewie-
sen werden. Der Surfactant vom Menschen könnte als
Vorlage für die unbegrenzte, gentechnologische Produk-
tion eines natürlichen Surfactants dienen. Pharmakody-
namische Aspekte der Surfactantsubstitution, Indikatio-
nen für eine exogene Surfactantzufuhr sowie das Mana-
gement bei Patienten mit Surfactantsubstitution müssen
weiter untersucht werden. Der exogene Surfactant stellt
ein wirksames Mittel dar zur Behandlung und Präven-
tion schwerer respiratorischer Störungen bei Neugebore-
nen, Kindern und Erwachsenen.
Schlüsselwörter: Fruchtwasser, hyalines Membransyndrom, Surfactant.
Resume
Substitution de surfactant naturel dans le syndrome de
detresse respiratoire
Les surfactants naturels consistent en proteines et en
lipides uniques. Leur efficacite ä entrainer une fonction
pulmonaire subnormale en cas de deficit en surfactant
devrait etre etablie avant tout essai clinique. Des tests
rigoureux sont necessaires pour documentor la variabi-
lite lot par lot, dans Tactivite de surface et exclure
des contaminants toxiques. Jusqu'ä cette date des essais
cliniques randomines chez de petits enfants prematures
ont demontre une amelioration nette de la fonction
pulmonaire et une diminution de Fincidence des compli-
cations aigues (pneumothorax, emphyseme interstitiel).
Uadministration de surfactant humain ä la naissance ou
lors de SDR graves diminue les morts et l'incidence des
dysplasies bronchopulmonaires. Bien que le surfactant
homologue ne soit peut etre pas plus avantageux que le
surfactant heterologue en tenne d'effets aigus benefiques
sur la fonction pulmonaire, la securite et Fefficacite
du surfactant animal dans amelioration de 1'evolution
restent a etablir. le surfactant humain peut servir de
modele pour le surfactant naturel illimite produit par
genie genetique. Les aspects pharmacodynamiques de la
substitution de surfactant, les indications du surfactant
exogene et la prise en charge des patients necessitant une
substitution de surfactant restent ä etudier. Le surfactant
exogene offre un potentiel de traitement ou de preven-
tion des detresses respiratoires graves chez les nouveaux-
nes, les enfants et les adultes.
Mots-cles: Liquide amniotique, surfactant, syndrome de detresse respiratoire.
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